Allergan also delivered strong performance. On a full quarter basis, Allergan sales grew 13 percent in constant currency to $1.75 billion for its final quarter, although only two weeks were included in the results reported today. The strong performance was broad based, driven by continued strength across the company’s Eye Care, Botox and Aesthetics businesses. Eye Care grew 14 percent in constant currency, driven by Restasis®, Lumigan® and Ozurdex®. Botox® increased 16 percent in constant currency, driven by growth in therapeutic indications. And, Skin Care, Breast Aesthetics and Facial Aesthetics were up on a combined basis. Internationally, Allergan also achieved strong growth, with all three units – Eye Care, Medical Aesthetics and Specialty Care achieving double-digit growth.